AN2 Therapeutics, Inc.
ANTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $41 | $484 | $146 | $289 |
| - Cash | $21 | $16 | $27 | $12 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $20 | $468 | $119 | $276 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $3 | $5 | -$41 | -$22 |
| % Margin | – | – | – | – |
| Net Income | -$51 | -$65 | -$41 | -$22 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.72 | -2.74 | -2.79 | -1.5 |
| % Growth | 37.2% | 1.8% | -86% | – |
| Operating Cash Flow | -$49 | -$53 | -$33 | -$20 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$49 | -$53 | -$33 | -$20 |